4 citations · 7 across the 16 of their papers we have counts for
16 papers
Meta-Analysis of High-Dimensional Surrogate Markers
Arthur Hughes, Rodolphe Thiébaut, Layla Parast +1
When direct measurement of a clinically relevant primary endpoint in a clinical trial is infeasible, a surrogate endpoint may be used instead to infer treatment effects. Trial-leve…
A Functional-Class Meta-Analytic Framework for Quantifying Surrogate Resilience
Emily Hsiao, Layla Parast
A surrogate marker is a biomarker or other physical measurement used to replace a primary outcome in clinical trials to evaluate a treatment effect when the primary outcome of inte…
A Causal Framework for Evaluating Jointly Longitudinal Outcomes and Surrogate Markers: A State-Space Approach
Silvaneo V. dos Santos, Layla Parast
Surrogate markers offer the potential to reduce the burden of data collection by replacing costly or invasive primary outcomes with more accessible measurements, provided that they…
Correcting for Missing Data When Evaluating Surrogate Markers in a Clinical Trial
Sarah C. Lotspeich, P. D. Anh. Nguyen, Layla Parast
Evaluating treatment effects is critical in clinical trials but sometimes involves lengthy, invasive, or costly follow-up procedures. In these cases, surrogate markers, which provi…
A Bayesian Critique of Rank-Based Methods for Surrogate Marker Evaluation
Pietro Carlotti, Layla Parast
Surrogate markers are often employed in clinical trials to replace primary outcomes that may be difficult, expensive, or time-consuming to measure directly. These markers can accel…
Resilience Measures for the Surrogate Paradox
Emily Hsiao, Lu Tian, Layla Parast
Surrogate markers are often used in clinical trials to evaluate treatment effects when primary outcomes are costly, invasive, or take a long time to observe. However, reliance on s…
Assessing Surrogate Heterogeneity in Real World Data Using Meta-Learners
Rebecca Knowlton, Layla Parast
Surrogate markers are most commonly studied within the context of randomized clinical trials. However, the need for alternative outcomes extends beyond these settings and may be mo…
Efficient Testing Using Surrogate Information
Rebecca Knowlton, Layla Parast
In modern clinical trials, there is immense pressure to use surrogate markers in place of an expensive or long-term primary outcome to make more timely decisions about treatment ef…
Model-free Approach to Evaluate a Censored Intermediate Outcome as a Surrogate for Overall Survival
Xuan Wang, Tianxi Cai, Lu Tian +1
Clinical trials or studies oftentimes require long-term and/or costly follow-up of participants to evaluate a novel treatment/drug/vaccine. There has been increasing interest in th…
Semiparametric Joint Modeling to Estimate the Treatment Effect on a Longitudinal Surrogate with Application to Chronic Kidney Disease Trials
Xuan Wang, Jie Zhou, Layla Parast +1
In clinical trials where long follow-up is required to measure the primary outcome of interest, there is substantial interest in using an accepted surrogate outcome that can be mea…
Group Sequential Testing of a Treatment Effect Using a Surrogate Marker
Layla Parast, Jay Bartroff
The identification of surrogate markers is motivated by their potential to make decisions sooner about a treatment effect. However, few methods have been developed to actually use…
Robust Evaluation of Longitudinal Surrogate Markers with Censored Data
Denis Agniel, Layla Parast
The development of statistical methods to evaluate surrogate markers is an active area of research. In many clinical settings, the surrogate marker is not simply a single measureme…
Towards Optimal Use of Surrogate Markers to Improve Power
Xuan Wang, Layla Parast, Lu Tian +1
Motivated by increasing pressure for decision makers to shorten the time required to evaluate the efficacy of a treatment such that treatments deemed safe and effective can be made…
Using a Surrogate with Heterogeneous Utility to Test for a Treatment Effect
Layla Parast, Tianxi Cai, Lu Tian
The primary benefit of identifying a valid surrogate marker is the ability to use it in a future trial to test for a treatment effect with shorter follow-up time or less cost. Howe…
Doubly-robust evaluation of high-dimensional surrogate markers
Denis Agniel, Layla Parast, Boris Hejblum
When evaluating the effectiveness of a treatment, policy, or intervention, the desired measure of effectiveness may be expensive to collect, not routinely available, or may take a…
Evaluating Surrogate Marker Information using Censored Data
Layla Parast, Tianxi Cai, Lu Tian
Given the long follow-up periods that are often required for treatment or intervention studies, the potential to use surrogate markers to decrease the required follow-up time is a…